Participated · Series A · Jul 2026

smartbax pursues novel small-molecule antibiotics with a lead program that was in-licensed from AiCuris and targets an unexploited step in lipopolysaccharide (LPS) biosynthesis. The lead candidate has demonstrated in vivo efficacy, including against multidrug-resistant pathogens, and shows potential for oral administration; the company plans to complete preclinical work and submit an IND. In parallel, smartbax is developing proprietary programs that activate bacterial hydrolases to trigger bacterial self-digestion, targeting both Gram-positive and Gram-negative pathogens and showing efficacy against biofilms with no observed development of resistance so far. The company was founded in 2021 with scientific origins at the Technical University of Munich and benefitted from early support including €700,000 from BIVF and recognition tied to the m4 Award. Financially, smartbax has expanded its pre-Series A to €6.3 million to fund IND-enabling studies and pipeline development.

Participated · Seed · Apr 2026

Tacalyx focuses on discovery and development of antibodies against tumour associated carbohydrate antigens (TACAs) for cancer treatment. The company is developing modalities including antibody drug conjugates (ADCs) and other antibody-based therapies using a proprietary technology platform to exploit TACAs as targets. Its lead disclosed programme is TCX-201, an ADC directed at an undisclosed TACA, which the company plans to advance through preclinical development with proceeds from its recent financing. Tacalyx is expanding a differentiated pipeline of programmes built on its platform. The company is led by CEO Jean Engela and is headquartered in Berlin, Germany.

Led · Series D · Apr 2026

Led by founder and CEO David Benshoof Klein, Click Therapeutics develops, validates, and commercializes regulated, clinically validated prescription mobile applications intended to treat unmet medical needs. The company uses a proprietary platform-based approach that leverages patient-centric design and AI-based technologies to drive engagement and clinical outcomes. Its pipeline spans indications in psychiatry, neurology, oncology, immunology, and cardiometabolic disease. Click has secured FDA authorizations for CT-132 (episodic migraine) and Rejoyn (major depressive disorder, co-developed with Otsuka Pharmaceuticals). The company holds an IP portfolio that includes 63 granted patents. Financially, Click recently closed a $50M Series D led by Boehringer Ingelheim and previously completed a strategic partnership and Series C financing with Medidata and Dassault Systèmes. As part of the latest transaction, Boehringer agreed to transfer full commercial and marketing authorization rights for CT-155 to Click, positioning the company for commercialization activities.

Led · Seed · Jan 2026

TECregen pioneers thymus regeneration with a pipeline of differentiated thymopoietic biologics designed to revitalize and expand thymic epithelial cells (TECs) and replenish T-cell populations. Its therapeutic approach targets conditions driven by impaired T-cell responses, aiming to boost immune recovery after transplantation or cytotoxic therapy, promote lifelong immune health, and improve immune surveillance against cancer. The platform also holds promise across broader immunology, oncology, and rare-disease indications. Fresh capital from a CHF 10 million seed financing provides the resources to advance preclinical programs toward first-in-human studies. The company has reinforced its leadership by appointing seasoned biotech executive Dr. Bo Rode Hansen as chairman to guide strategic growth. Backed by a syndicate of specialized life-science investors, TECregen is positioning itself at the forefront of immune-restoration therapeutics. No revenue or user metrics have been disclosed, as the company remains in the preclinical stage.

Participated · Series B · May 2025

Nuevocor is an IND-stage biotech developing novel therapies for genetic cardiomyopathies driven by aberrant mechanobiology using its proprietary PrOSIATM platform. Its lead candidate, NVC-001, is a first-in-class AAV-based gene therapy designed to reduce forces to the nucleus and restore nuclear envelope integrity in LMNA-related dilated cardiomyopathy (LMNA DCM). NVC-001 has shown dramatic survival benefits in preclinical models, high transduction levels, and a clean safety profile in GLP toxicology studies and large animal models. The company plans a first-in-human, open-label, multicenter, ascending single-dose Phase 1/2 trial in early 2026 with sites across the U.S. and Europe and will run a concurrent natural history study. Proceeds from the financing will support the Phase 1/2 trial through clinical proof-of-concept and the company will establish an office in Paris to support clinical development. Nuevocor positions its approach to treat shared disease pathways across multiple cardiomyopathies rather than individual gene replacement, targeting indications not amenable to traditional gene replacement therapy. Nuevocor is a Singapore-headquartered, preclinical-stage biotech company working in gene therapy. The article does not provide product- or pipeline-level details. According to ACRA filings accessed by DealStreetAsia (DATA VANTAGE), the company has raised an additional $11.6 million in funding. The filings indicate the capital came from existing investors but do not name them. The report does not disclose the funding instrument, use of proceeds, operating metrics, past rounds, founding year, or specific future plans. Nuevocor is a preclinical-stage biopharmaceutical company focused on developing adeno-associated virus (AAV) gene therapies for genetically defined cardiac diseases with high unmet need. Its lead program targets lamin A/C dilated cardiomyopathy (LMNA DCM) and is built on decades of research by its scientific co-founders. The company leverages novel technologies from co-founders at A*STAR and gene therapy and cardiac disease modelling expertise from collaborators at Stanford and the National University of Singapore. Led by founding CEO Dr Yann Chong Tan, Nuevocor aims to advance its lead AAV-based program through preclinical development. The company also plans to use its target discovery platform to address other untreatable cardiomyopathies. Nuevocor closed a $24M Series A to support these efforts.